| Patient | Jesse Owens |
|---|---|
| Date of birth | 1960-09-12 |
| Identifiers | MRN HR-ML042-SYN; SSN (made up) 000-42-8319 |
| Document date | 2026-09-30 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six weeks after left upper lobectomy: pathology and the plan from here. [S]
Mr. Owens returns six weeks after his thoracoscopic left upper lobectomy. He went home on the third day, needed no opioid after discharge, and stopped acetaminophen two weeks ago. Pathology shows only 0.7 cm of residual cancer with 6 percent viable tumor, a major pathologic response, with clear margins and no cancer in any of 16 lymph nodes. Dr. Halvorsen-Pierce reviewed the options with him last week. He walks 2 km a day and starts the pulmonary rehabilitation program next week. He gets mildly short of breath on two flights of stairs. He has not smoked for four months. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Operation | Thoracoscopic left upper lobectomy with lymph node dissection; three days in hospital; no complications |
| Pathology | ypT1a N0 (0 of 16), R0, major pathologic response (6 percent viable tumor) |
| Tobacco | Abstinent four months on varenicline |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy returning; weight 74.6 kg; no fever |
| Respiratory | Positive | Mild breathlessness on two flights of stairs; no cough or sputum |
| Musculoskeletal | Positive | Mild aching at the port sites |
| Endocrine | Negative | No cold intolerance or constipation |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Relieved and hopeful; PHQ-2 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 2026-05-26 to 2026-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 2026-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 2026-05-26 to 2026-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 2026-05-26 to 2026-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 2026-06-02 to 2026-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 2026-06-03 to 2026-07-31 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery | 1000 mg every 8 hours as needed | Oral route | 2026-08-22 to 2026-09-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-30 | Body height | 178 | cm | S |
| 2026-09-30 | Body weight | 74.6 | kg | S |
| 2026-09-30 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 2026-09-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-30 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-30 | Heart rate | 76 | /min | S |
| 2026-09-30 | Respiratory rate | 16 | /min | S |
| 2026-09-30 | Body temperature | 36.6 | Cel | S |
| 2026-09-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-30 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.5-17.5 g/dL | Low | S |
| 2026-09-30 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-09-30 | Neutrophils [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-09-30 | Platelets [#/volume] in Blood by Automated count | 246 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-09-30 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-09-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-30 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-09-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 2026-09-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-09-30 | Thyrotropin [Units/volume] in Serum or Plasma | 4.6 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 2026-09-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-09-30 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-09-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 74.6 kg; blood pressure 122/76, pulse 76; oxygen saturation 96 percent |
| Respiratory | Breath sounds slightly reduced at the left apex; no crackles; port-site incisions healed |
| Cardiovascular | Regular rhythm; no edema |
| Lymph nodes | No supraclavicular nodes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | resolved | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
| Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor) | active | confirmed | Z90.2 | S — Synthetic consequence of the synthetic operation. |
| Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on varenicline | active | confirmed | F17.211 | S — Synthetic modern entry linked to his documented smoking. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | After treatment, as indicated | Completed today | Hemoglobin 13.4 (recovering), white cells 7.0, neutrophils 4.3, platelets 246 |
| Laboratory | Thyroid, liver, kidney and glucose tests after immunotherapy | After the last dose and for symptoms; thyroid every 6 to 12 weeks for a year after a rise | Completed today | TSH 4.6 (slightly high) with free T4 1.1; ALT 24, AST 22, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 92 |
| Imaging | Surveillance chest CT | Every six months for two to three years after curative treatment, then yearly low-dose CT | Due | First surveillance CT booked for six months after surgery |
| Imaging | Routine brain MRI, PET-CT and circulating tumor markers for surveillance | Not recommended in stage I to III | Not indicated | Not used without symptoms |
| Self-management | Pulmonary rehabilitation after lung resection | 6 to 12 week program after surgery | Referred | Starts next week |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent four months; varenicline to 24 weeks |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 0 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Mild breathlessness on two flights; no cough |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | None |
| Survey | Cancer-related fatigue | Every visit | Completed today | Mild, improving |
| Self-management | Immunizations after treatment | Per the adult schedule | Due | Influenza, COVID-19, RSV and zoster vaccines at the wellness visit in three weeks |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Schneider BJ, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncol Pract 2020;16(2):83-86 (PMID 32045555) (2020); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)
Follow-up: Pulmonary rehabilitation from next week. Annual wellness visit in three weeks. Surveillance CT in about six months. Call for new cough, hemoptysis, bone pain, headache or weight loss. Next scheduled visit 2026-10-21: subsequent annual wellness visit. [S]